Clinical Trials Office (CTO)
The Clinical Trials Office within the Carole and Ray Neag Comprehensive Cancer Center is focused on supporting high-quality cancer research and thus help promote better care for cancer patients at UConn Health. The staff consists of highly qualified, trained and certified professionals who are committed to assisting in the planning, development, implementation, and regulatory oversight of all phases of cancer clinical trials.
The office was created under the Medical Directorship of Pramod K. Srivastava, Ph.D., M.D., and Director of the Cancer Center and provides a dedicated team to enable Hematology and Medical Oncology faculty to bring to UConn Health, innovative treatment options that otherwise would not be available to cancer patients. The Clinical Trials Office actively partners with various cancer cooperative groups, pharmaceutical firms, and other academic centers to bring revolutionary cancer research studies to UConn Health. By supporting clinical research, the office aids UConn Health to meet its goals of excellence in patient care, education, and research. It also engages with other cancer research programs within UConn Health to reach out to the community to educate patients about clinical trials, create awareness on cancer prevention, and increase patient participation in clinical trials.
Current Membership Status:
- NRG Oncology - which consist of three cooperative groups National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).
- Cancer Trials Support Unit (CTSU)
- The Academic and Community Cancer Research United (ACCRU)
Current Therapeutic Studies Opened to Accrual:
- A Phase I Study of OncoImmunome for the Treatment of Stage III/IV Ovarian Carcinoma (US FDA IND # 16016)
- A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers.
- S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.
- A Phase 1, Open-Label, Dose Escalation Study Of PF-04518600 As A Single Agent And In Combination With PF-05082566 In Patients With Selected Locally Advanced Or Metastatic Carcinomas.
Pramod Srivastava, Ph.D., M.D., Clinical Trials Office Medical Director
Wanita Thorpe, M.B.A., Clinical Trials Office Administrative Manager
Quratulain Ali, M.P.H., CCRP, MSHS, Clinical Trials Office Supervisor
Kerrylin Burke, M.S., H.S.M., Administrative Fiscal Assistant
Katarzyna Nastri, B.A., CCRP, Clinical Research Associate, Compliance and Quality
Ektor Rafti, M.D., Clinical Research Associate
Christopher Sampson, B.S., CCRP, Clinical Research Associate
Margaret Toro, CCRC, Clinical Research Associate
Chih-Chen Wong, M.S., CCRP, Clinical Research Associate
Phase 1 Study of OncoImmunome for the Treatment of Stage III/IV Ovarian Carcinoma
The U.S. Food and Drug Administration (FDA) has approved our Investigational Drug Application for this clinical study at UConn Health for patients with advanced stage (stage III or IV) ovarian cancer. Patients shall receive the standard of care treatment including surgery and chemotherapy, followed by a personalized cancer vaccine, which will be developed for each patient. Blood and cancer samples will be obtained from each patients at the time of surgery, and shall be used to generate and compare the genomic information in each patient’s cancer. Personalized vaccines will be made on basis of the genetic differences between the blood and cancer samples of each patient. The patients shall receive the vaccines by an injection in an outpatient setting, once every month for 6 months. Learn more about the new clinical trial and its enrollment.
About Clinical Trials
Clinical trials are research studies in which real people participate as volunteers. Clinical research studies (also known as clinical trials) are designed to evaluate health risks and to test new approaches to the diagnosis, treatment and prevention of specific diseases. These studies play a significant role in the development of new treatments and medications for various diseases and conditions. A clinical trial could be a treatment option for you.
The goal of research is to find better ways to treat or identify cancer and help cancer patients. Clinical trials test many types of treatment, such as new drugs, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as gene therapy. Some clinical trials study the effects of our standard treatments on patient quality of life during and after completion of the treatment. The knowledge that may be gained from this type of work can be of great value to our society.
To ensure the safety of volunteers who enroll in clinical studies, each project must be approved by an Institutional Review Board (IRB). The goal of the IRB is to ensure safety, welfare and well-being of study participants. During the review process, the IRB evaluates the potential risks and benefits associated with the study and decide whether or not to approve it.
This information is provided by the National Library of Medicine (NLM).